Skip to main content

Facilitating Collaborations to Develop Combination Investigational Cancer Therapies Workshop Summary (2012) / Chapter Skim
Currently Skimming:

Acronyms
Pages 101-104

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 101...
... Acronyms AIDS acquired immunodeficiency syndrome BATTLE Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination BRAF Rapidly Accelerated Fibrosarcoma (B family) CaBIG cancer Biomedical Informatics Grid CDER Center for Drug Evaluation and Research CDRH Center for Devices and Radiological Health CEO chief executive officer CGL chronic granulocytic leukemia CITN Cancer Immunotherapy Trials Network CMS Center for Medicare & Medicaid Services CRADA Cooperative Research and Development Agreement CTEP Cancer Therapy Evaluation Program CTLA-4 Cytotoxic T-Lymphocyte Antigen 4 DCE-MRI dynamic contrast enhanced-magnetic resonance imaging DOJ Department of Justice EGFR epidermal growth factor receptor EMA European Medicines Agency ER estrogen-receptor 101
Read the entire page →
From page 102...
... 102 COLLABORATIONS TO DEVELOP COMBINATION CANCER THERAPIES FDA Food and Drug Administration FNIH Foundation for the National Institutes of Health FTC Federal Trade Commission GSK GlaxoSmithKline HER2 human epidermal growth factor receptor 2 HIV Human Immunodeficiency Virus HPV human papillomavirus IGF insulin-like growth factor IIP instantaneous inhibitory potential IND Investigational New Drug IP intellectual property IRB Institutional Review Board I-SPY TRIAL Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular analysis LCMV lymphocytic choriomeningitis virus MAPK mitogen-activated protein kinase MEK mitogen-activated protein kinase kinase MET Methylnitronitrosoguanidine-HOS (Human osteosarcoma) Transforming gene MTA Material Transfer Agreement mTORC1 mammalian target of rapamycin complex-1 NCDDG National Cooperative Drug Discovery Groups NCI National Cancer Institute NERF non-exclusive royalty-free NIAID National Institute of Allergy and Infectious Diseases NIH National Institutes of Health NOD non-obese diabetic OS overall survival PathCR pathological complete response PET positron emission tomography PFS progression-free survival PI3K phosphatidylinositol 3-kinase PPTP Pediatric Preclinical Testing Program R&D research and development
Read the entire page →
From page 103...
... 103 ACRONYMS SOC standard of care START Standard Terms of Agreement for Research Trial VEGF vascular endothelial growth factor
Read the entire page →

Key Terms



This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.